CAS: 461-05-2; 3-Hydroxy-4-(Trimethylammonio)Butanoate Hydrochloride

上下游产品

CAS号39082-00-3 4’-氯乙酰基乙酰苯胺 | CAS号142-04-1 苯胺盐酸盐 | CAS号5080-50-2 乙酰-L-肉毒碱盐酸盐 | CAS号142674-34-8 3-(6,6,7,7,8,8,... | CAS号142674-38-2 3-(12,12,13,13,... | CAS号142674-35-9 3-tridecanoylox... | CAS号461-06-3 γ-三甲铵-β-羟基丁酸 | CAS号142674-37-1 3-(12,12,13,13,... | CAS号6538-82-5 3-羧基-N,N,N-三甲基-...

左卡尼汀相关物质a置于platinum(Iv) Oxide 氢气体系中,用 乙醇 作为反应溶剂,化学反应生成 Dl-肉碱盐酸盐
参考文献:Fujita,T. Et Al.,Chemical And Pharmaceutical Bulletin,1961,Vol. 9,P. 661-665
标题:Fujita,T. Et Al.,Chemical And Pharmaceutical Bulletin,1961,Vol. 9,P. 661-665

专利信息

专利号:US-6365611-B1
优先权日:1997-06-11
标 题 :Pentaerythrite derivatives, the production and use thereof and intermediate products for the synthesis of the same
发明人：KOENIG GERD; HESS ULRICH; WINDECK ANNE-KATRIN; BROSIG HOLGER
权利人:ISIS PHARMA GMBH
摘要:The invention relates to novel compounds derived from pentaerythrite compounds of formula (XII) and (XVI), which can be used as pharmaceutically active substances, specially in the treatment of cardiac and circulatory diseases.

专利号:US-4221869-A
优先权日:1977-07-18
标题:Enzymatic synthesis of L-carnitine
发明人：VANDECASTEELE JEAN-PAUL; LEMAL JEANNINE
权利人:INST FRANCAIS DU PETROLE
摘要:L-carnitine is obtained by reacting 3-dehydrocarnitine or one of its salts, in aqueous medium, simultaneously with: (a) carnitine dehydrogenase, (b) a coenzyme utilized by carnitine dehydrogenase for reducing dehydrocarnitine, preferably nicotinamide adenine dinucleotide, and (c) a reducing agent for the coenzyme, the coenzyme (b) and carnitine dehydrogenase being preferably used in catalytic amount.

专利号:US-2022370393-A1
优先权日:2019-10-16
标 题 :Method and composition for increasing muscle protein synthesis
发明人：BELLAMINE AOUATEF; GLAB STANISLAW; DURKEE SHANE
权利人:CAPSUGEL BELGIUM NV
摘要:A method and composition for increasing muscle protein synthesis in mammals is disclosed. In one embodiment, the mammals are administered a protein building composition comprising at an amino acid derivative including L-carnitine and a nitrogenous organic acid including creatine. In a particular embodiment, the creatine is in an acid resistant capsule delivery form. The ratio of L-carnitine to creatine can be from about 10:1 to about 1:1. The protein building composition can be administered in a monolithic enteric capsule.

专利号:US-2022370392-A1
优先权日:2019-10-16
标 题:Method and Composition for Increasing Muscle Protein Synthesis
发明人：BELLAMINE AOUATEF; GLAB STANISLAW; DURKEE SHANE
权利人:BELLAMINE AOUATEF; CAPSUGEL BELGIUM NV
摘要:A method and composition for increasing muscle protein synthesis in mammals is disclosed. In one embodiment, the mammals are administered a protein building composition comprising at an amino acid component including L-carnitine and a nitrogenous organic acid including creatine. In a particular embodiment, the creatine is in a solution with L-carnitine. The ratio of L-carnitine to creatine can be from about 10:1 to about 1:1. The protein building z composition can be administered in a monolithic enteric capsule.

专利号:US-10888571-B2
优先权日:2015-12-18
标 题:Method and composition for increasing muscle protein synthesis and/or functional strength in mammals
发明人：BELLAMINE AOUATEF; ZHIVKOVICH ILYA; FREITAS ULLA
权利人:LONZA CONSUMER HEALTH INC
摘要:A method and composition for preserving muscle mass and function by increasing muscle protein synthesis and/or decreasing muscle protein degradation in mammals is disclosed. In one embodiment, the mammals are administered a protein building composition comprising at least two of an essential amino acid, an amino acid derivative, and a nitrogenous organic acid. In a particular embodiment, the protein building composition comprises leucine, L-carnitine, and creatine. The protein building composition can decrease TNF-α and increase mTOR expression in muscle.

专利号:US-2020129464-A1
优先权日:2018-10-29
标题 :Method and Composition for Increasing the Bioavailability of Carnitine
发明人：BELLAMINE AOUATEF
权利人:LONZA AG
摘要:A method and composition for improving the health of a mammal, such as by increasing the bioavailability of L-carnitine to the mammal. The method and composition includes administering an effective amount of branched chain amino acid metabolite substituted carnitine compound. The method and composition also includes administering an effective amount of branched chain amino acid metabolite substituted carnitine compound in order to improve the health of the mammal. The mammal's health may be improved by providing increased energy, anti-aging, anti-inflammatory and/or anti-oxidant properties, increased mitochondrial function, increased brain function, weight management and/or obesity management properties, exercise endurance and exercise recovery, increased protein synthesis, mTOR pathway activation, and/or Kreps cycle stimulation.